New Apps For AI in mRNA With Anima Biotech's Yochi Slonim

Business Of Biotech

We love to hear from our listeners. Send us a message.

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim's not in software development anymore. Not for the software industry, anyway. He's now leveraging his tech chops to develop something with far more potential impact: drugs. On this epsiode of the Business of Biotech, we'll learn about his foray into biopharmaceuticals with Anima Biotech, a company he’s been building for the past ten years and which boasts pipeline partnerships with heavyweights Abbvie, Takeda, and Lilly.

Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

Chapters

1. Tech Entrepreneur's Biotech Venture (00:00:00)

2. Transition Into Biotech and AI Value (00:11:08)

3. AI Imaging and Disease Diagnosis (00:27:58)

4. AI Drug Discovery Platform and Applications (00:33:21)

5. Drug Development Technology and Pipeline Integration (00:39:23)

6. Anima Biotech's Unique AI Approach (00:50:07)